One of the world's leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with nearly 10,000 employees in locations spanning the globe and 2006 revenues of $3.2 billion. In 2007, Genzyme was chosen to receive the National Medal of Technology, the highest honor awarded by the President of the United States for technological innovation. In 2006 and 2007, Genzyme was selected by FORTUNE as one of the "100 Best Companies to Work for" in the United States.
With many established products and services helping patients in nearly 90 countries, Genzyme is a leader in the effort to develop and apply the most advanced technologies in the life sciences. The company's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant, and diagnostic testing. Genzyme's commitment to innovation continues today with a substantial development program focused on these fields, as well as immune disease, infectious disease, and other areas of unmet medical need.
This press release contains forward-looking statements, including the
expectation that the expansion of Allston Landing will help sustain the
continued growth of Genzyme's products, expected job creation estimates,
the completion of the Allston Landing expansion in two years and the
certification of the expansion under the U.S. Green Building Council's
Green Building Rating System. These statements are subject to risks and
uncertainties that could cause actual results to differ materially from
those projected in these forward-looking statements. These risks and
uncertainties include Genzyme's ability to obtain and maintain the
requisite governmental or other approvals to implement its plans for the
Allston facility, and the risks and uncertainties described in reports
filed by Genzyme with the U.
|SOURCE Genzyme Corp.|
Copyright©2007 PR Newswire.
All rights reserved